INTRODUCTION {#s1}
============

Gastric cancer is the third most common cause of death from malignant disease in men (fifth in women) worldwide \[[@R1]\]. The prognosis for patients with unresectable advanced or recurrent gastric cancer remains poor, with a median survival time of less than 1 year in individuals receiving conventional therapy \[[@R2]-[@R8]\]. The combination of trastuzumab, an antibody targeted to HER2, with chemotherapy has yielded a survival benefit for patients with HER2-positive gastric or gastro-esophageal junction cancer \[[@R7]\], with HER2-positive tumors accounting for 7 to 17% of all gastric cancers \[[@R9]-[@R11]\]. Further research is thus warranted to identify new therapeutic targets for gastric cancer patients.

The *MET* proto-oncogene encodes the receptor tyrosine kinase c-MET. The binding of its ligand, hepatocyte growth factor, to MET results in tyrosine phosphorylation of the receptor and activation of downstream signaling molecules. Oncogenic activation of *MET* suppresses apoptosis and promotes cell survival, proliferation, migration, and differentiation as well as gene transcription and angiogenesis \[[@R12]\]. In gastric cancer, such activation of *MET* has been attributed to gene amplification \[[@R13]-[@R15]\]. However, the prevalence of *MET* amplification has varied among studies \[[@R13]-[@R21]\], possibly as a result of differences in the methods applied. This uncertainty led us to determine the prevalence of *MET* amplification in 266 formalin-fixed, paraffin-embedded (FFPE) specimens of gastric cancer obtained during surgery. To ensure the efficient detection of *MET* amplification, we adopted a sequential approach involving PCR-based determination of gene copy number followed by confirmatory FISH analysis. Moreover, to assess the potential of *MET* amplification as a therapeutic target in gastric cancer, we investigated its impact on cell survival and signal transduction.

RESULTS {#s2}
=======

MET amplification in gastric cancer cell lines {#s2_1}
----------------------------------------------

We first applied FISH (Figure [1A](#F1){ref-type="fig"}) and a real-time PCR--based method (Figure [1B](#F1){ref-type="fig"}) to examine *MET* copy number in gastric cancer cell lines whose *MET* amplification status was previously determined \[[@R22]\]. In gastric cancer cell lines negative for *MET* amplification, including KATO III, SNU1, SNU216, MKN1, MKN7, HSC39, MKN28, and NUGC3, the copy number of *MET* as determined by the PCR-based assay ranged between 1.3 and 3.3. In contrast, cell lines positive for *MET* amplification, including Hs746T, MKN45, and SNU5, showed *MET* copy numbers of 21.3, 21.3, and 17.9, respectively. The PCR-based assay thus revealed a high copy number for *MET* only in gastric cancer cell lines previously shown to be positive for *MET* amplification by FISH.

![Amplification of *MET* in gastric cancer cell lines\
*A*, FISH analysis of cell lines positive or negative for *MET* amplification (amp). Each image shows a single cancer cell, with green and red signals corresponding to CEN7p and the *MET* locus, respectively. *B*, Evaluation of *MET* copy number in gastric cancer cell lines with a PCR-based assay.](oncotarget-04-009-g001){#F1}

MET amplification in gastric cancer specimens {#s2_2}
---------------------------------------------

To determine the prevalence of *MET* amplification in advanced gastric cancer, we examined 266 FFPE specimens of surgically resected primary gastric tumors. Most of the patients were male (68.8%) and had undifferentiated-type gastric cancer (62.8%), including mucinous adenocarcinoma, signet ring cell adenocarcinoma, and poorly differentiated adenocarcinoma (Table [1](#T1){ref-type="table"}). The median age was 63 years, with a range of 31 to 91 years.

###### Characteristics of the 266 study patients

  --------------------------------------
  Characteristic           n
  ------------------------ -------------
  **Sex**\                 183 (68.8%)
   Male                    

   Female                  83 (31.2%)

  **Pathological stage**   

   I                       25 (9.4%)

   II                      31 (11.7%)

   III                     77 (28.9%)

   IV                      133 (50.0%)

  **Histology**            

   Differentiated type     99 (37.2%)

   Undifferentiated type   167 (62.8%)
  --------------------------------------

The patients had a median age of 63 years (range, 31 to 91 years).

The PCR-based assay revealed that the median *MET* copy number for the 266 cases was 1.7, with a range of 0.41 to 21.3 copies (Figure [2A](#F2){ref-type="fig"}). Given that gastric cancer cell lines with *MET* amplification have been found to have a high copy number for *MET* \[[@R23]\], we arranged all cases in the order of *MET* copy number and performed FISH analysis for the 15 cases with the highest copy numbers (Table [2](#T2){ref-type="table"}). *MET* amplification was detected by FISH in four of these cases (G72, G289, G322, and G181), which had a *MET* copy number of at least 4, whereas six cases (G276, G233, G295, G170, G307, and G231) with a copy number of less than 4 did not exhibit *MET* amplification (Figure [2B](#F2){ref-type="fig"}, Table [2](#T2){ref-type="table"}). The remaining five cases (G331, G223, G217, G118, and G42) were not assessable by FISH analysis because of a lack of hybridization signals.

![Amplification of *MET* in surgical specimens of gastric cancer\
*A*, *MET* copy number determined with a PCR-based assay for 266 FFPE surgical specimens of gastric cancer. A *MET* copy number of \>4 was observed in five cases. *B*, FISH analysis of gastric cancer specimens among the 15 samples with the highest *MET* copy numbers as determined with the PCR-based assay. Green and red signals correspond to CEN7p and the *MET* locus, respectively. Higher magnification images of individual cancer cells are shown in the insets. The specimens are grouped into those determined to be positive of negative for *MET* amplification by FISH.](oncotarget-04-009-g002){#F2}

###### Characteristics of the 15 patients with the highest MET copy numbers

  Case no.   MET copy number   MET/CEN7p   Sex   Age (years)   Histology   Stage   OS (days)
  ---------- ----------------- ----------- ----- ------------- ----------- ------- -----------
  G72        21.3              5.9 (+)     M     66            U           IV      157
  G289       6.84              5.2 (+)     F     48            U           IV      483
  G322       6.45              7.2 (+)     F     70            U           IV      84
  G331       6.14              ND          M     76            U           II      \>2764
  G181       4.02              6.6 (+)     F     52            U           IIIb    \>1977
  G223       3.92              ND          M     62            U           IIIa    \>3340
  G276       3.23              1.2 (−)     M     70            U           Ib      1089
  G233       3.09              1.2 (−)     F     63            U           IIIb    \>4732
  G217       3.02              ND          F     69            U           IIIa    \>3827
  G118       2.97              ND          M     66            U           IIIa    2650
  G295       2.89              2.0 (−)     M     74            U           IV      539
  G170       2.88              1.7 (−)     M     53            D           Ia      \>2088
  G42        2.87              ND          M     64            D           II      1907
  G307       2.85              1.3 (−)     M     60            U           IV      824
  G231       2.83              1.9 (−)     M     67            D           IIIa    \>2921

Abbreviations: ND, signals not detected; U, undifferentiated type; D, differentiated type. (+) or (−) denote positive or negative for MET amplification on the basis of the MET/CEN7p ratio; \> for OS indicates the patient was still alive.

We thus identified four out of 266 gastric cancer patients (1.5%) as having *MET* amplification. The clinical features of patients with or without *MET* amplification are shown in Tables [2](#T2){ref-type="table"} and [3](#T3){ref-type="table"}. All four patients with *MET* amplification had undifferentiated-type gastric cancer. We further examined the prognostic impact of *MET* amplification for all 266 patients but found that OS after surgery did not differ significantly between those with or without *MET* amplification (log-rank test, *P* = 0.3).

###### Clinical and pathological characteristics of gastric cancer patients classified according to MET amplification status

  Characteristic              MET amplification(+) (n = 4)   MET amplification(−) (n = 262)   P
  --------------------------- ------------------------------ -------------------------------- ----------------------------------------
  Median age (range), years   59 (48--70)                    63 (31--91)                      0.976
  Sex, n                                                                                      
   Male                       1 (25.0%)                      182 (69. 5%)                     0.091
   Female                     3 (75.0%)                      80 (30. 5%)                      
  Pathological stage, n                                                                       
   I                          0                              25 (9.5%)                        0.582[a](#fn-001){ref-type="table-fn"}
   II                         0                              31 (11.8%)                       
   III                        1 (25.0%)                      76 (29.0%)                       
   IV                         3 (75.0%)                      130 (49.6%)                      
  Histology, n                                                                                
   Differentiated type        0                              99 (37.8%)                       0.300[b](#fn-002){ref-type="table-fn"}
   Undifferentiated type      4 (100%)                       163 (62.2%)                      

Comparison between stages I + II and III + IV.

Comparison between intestinal-type and diffuse-type gastric cancer. P values were calculated with Student\'s two-tailed t test for age and the chi-square test for the other variables.

MET amplification is associated with increased sensitivity to MET-TKIs in gastric cancer cell lines {#s2_3}
---------------------------------------------------------------------------------------------------

To investigate the biological impact of *MET* amplification in gastric cancer, we first examined the effects of two highly selective MET receptor tyrosine kinase inhibitors (MET-TKIs), JNJ38877605 and SGX523, on the growth of gastric cancer cell lines positive or negative for *MET* amplification. The IC~50~ values of JNJ3887605 and SGX523 for inhibition of cell growth were 0.02 to 0.05 μM and 0.06 to 0.07 μM, respectively, for cells positive for *MET* amplification, whereas they were \>10 μM for *MET* amplification--negative cells (Figure [3A](#F3){ref-type="fig"}). An annexin V binding assay revealed that both MET-TKIs induced a substantial level of apoptosis in *MET* amplification--positive cells but were largely without effect in cell lines without *MET* amplification (Figure [3B](#F3){ref-type="fig"}). Immunoblot analysis showed that the MET-TKIs inhibited the phosphorylation of MET, AKT, ERK, and STAT3 in gastric cancer cells with *MET* amplification, whereas they had no effect on signaling events in those negative for *MET* amplification (Figure [3C](#F3){ref-type="fig"}). These findings thus indicated that gastric cancer cells with *MET* amplification are predominantly dependent on MET signaling for their growth and survival and are therefore rendered hypersensitive to MET-TKIs.

![Effects of MET-TKIs in human gastric cancer cell lines classified according to *MET* amplification status\
*A*, Effects of JNJ38877605 and SGX523 on cell growth as determined with the MTT assay. Data are means of triplicates from representative experiments. *B*, Cells were incubated in the absence or presence of 0.10 μM JNJ38877605 or 0.10 μM SGX523 for 48 h, after which the number of apoptotic cells was determined by staining with annexin V followed by flow cytometry. *C*, Cells were incubated in the absence or presence of 0.10 μM JNJ38877605 or 0.10 μM SGX523 for 48 h, after which cell lysates were prepared and subjected to immunoblot analysis with antibodies to phosphorylated (p) or total forms of MET, AKT, ERK, or STAT3 or with those to β-actin (loading control).](oncotarget-04-009-g003){#F3}

DISCUSSION {#s3}
==========

Activation of MET signaling promotes tumor cell growth, survival, migration, and invasion as well as tumor angiogenesis \[[@R24]\]. In gastric cancer, gain-of-function mutations of *MET* are exceedingly rare \[[@R25]-[@R27]\], with MET activation having been attributed mostly to gene amplification \[[@R13]-[@R15]\]. Previous studies based on FISH analysis have detected *MET* amplification in up to 4% of patients with gastric cancer \[[@R14], [@R16], [@R20]\]. On the other hand, an increase in *MET* copy number was found in 10 to 20% of gastric cancer patients by Southern blot analysis \[[@R17]-[@R19]\] or with a PCR-based assay \[[@R28], [@R29]\]. An increase in gene copy number in malignant tumors can result from at least two genetic mechanisms, gene amplification and polysomy. Gene amplification refers to a copy number gain for a specific gene (or group of genes) on a given chromosome arm without a change in copy number for genes located in other regions of the chromosome \[[@R30]\], whereas polysomy gives rise to a copy number gain for a given gene as a result of the presence of extra copies of the entire chromosome. Southern blot analysis and PCR-based copy number assays recognize a gain in gene copy number regardless of the underlying cause and are thus unable to distinguish gene amplification from polysomy, a limitation that is sometimes overlooked, with consequences for determination of the true prevalence of *MET* amplification in gastric cancer.

FISH analysis is a semiquantitative method that can be performed with two probes for determination of the number of signals for a target gene and for the centromeric portion of the corresponding chromosome. Given that the number of centromeric signals directly reflects the copy number of the chromosome, FISH analysis yields the copy number gain for the target gene from the ratio of the copy number of the gene to that of the chromosome. FISH is thus the gold standard for detection of gene amplification. However, the identification and counting of FISH signals are hampered by many factors including cutting artifacts, nuclear overlap, and heterogeneity of tumor specimens. Moreover, FISH is expensive and time-consuming, and it requires technical expertise \[[@R31]\]. The efficient determination of gene amplification in a large number of tumor specimens would thus benefit from the availability of a high-throughput screening assay. In this regard, PCR-based assays for determination of gene copy number are simple to perform and rapidly yield quantitative and reproducible results. Given that, among tumors showing a gain in gene copy number, those confirmed to be positive for gene amplification show the greatest increases in gene copy number \[[@R21], [@R23], [@R32], [@R33]\], we investigated the potential of a PCR-based assay for screening in order to select cases of gastric cancer for confirmation of *MET* amplification by FISH. We thus performed PCR-based screening for *MET* copy number in 266 surgically resected specimens of gastric cancer and then applied FISH analysis to the 15 cases showing the highest gene copy numbers. *MET* amplification was confirmed by FISH in four cases among the five with a *MET* copy number of at least 4; the remaining case (G331) was not assessable by FISH because of a lack of hybridization signals. *MET* amplification was not detected in the cases with a gene copy number of \<4. We therefore identified *MET* amplification at a frequency of 1.5% (4 out of 266 cases), consistent with values determined by FISH analysis in recent studies of gastric cancer \[[@R16], [@R20]\]. Our results thus suggest that screening for *MET* amplification with a PCR-based assay is an efficient means with which to reduce the number of specimens requiring evaluation by FISH analysis. As mentioned above, one specimen (G331) in the present study showed a high *MET* copy number (6.14 copies) but could not be confirmed positive for *MET* amplification because of the lack of a FISH result. The issue of how to identify *MET* amplification status in such cases remains to be resolved.

We examined the biological impact of *MET* amplification in gastric cancer cells by comparing the effects of the MET-TKIs JNJ38877605 and SGX523 between gastric cancer cell lines positive for *MET* amplification and those negative for this genetic alteration. In gastric cancer cells with *MET* amplification, the MET-TKIs markedly inhibited AKT, ERK, and STAT3 signaling and triggered apoptosis, whereas such effects were not evident in cells without *MET* amplification. To investigate whether attenuation of MET signaling by the MET-TKIs is related to the induction of apoptosis, we transfected gastric cancer cell lines with an siRNA specific for MET mRNA. Such transfection inhibited MET signal transduction as well as induced apoptosis in gastric cancer cell lines with *MET* amplification but not in those without it (data not shown). Our observations thus indicate that gastric cancer cell lines positive for *MET* amplification depend predominantly on constitutive activation of the encoded growth factor receptor for their survival and thus show high sensitivity to cell killing by MET-TKIs. Targeting of MET signaling by MET-TKIs is therefore a potentially valuable therapeutic approach for patients with *MET* amplification--positive gastric cancer. Indeed, the MET-TKI crizotinib (PF-02341066) was recently found to induce a radiographic response (partial response) and rapid clinical improvement in patients with advanced gastric cancer who were found to be positive for *MET* amplification by FISH \[[@R16]\]. Further investigation of the efficacy of MET-TKIs in patients with advanced gastric cancer positive for *MET* amplification is thus warranted.

Given the potential of MET-targeted therapy for gastric cancer with *MET* amplification, it is important to determine the prevalence of such gene amplification in patients with unresectable advanced gastric cancer, most of whom are currently treated with systemic chemotherapy. Our present study was limited to gastric cancer patients who underwent gastrectomy, and so further studies will be needed for patients with unresectable advanced tumors. Given the apparent low prevalence of *MET* amplification in gastric cancer, implementation of a sequential approach including screening with a PCR-based copy number assay followed by confirmatory FISH analysis should facilitate the identification of *MET* amplification in a large cohort of patients with unresectable advanced gastric cancer.

MATERIALS AND METHODS {#s4}
=====================

Cell culture {#s4_1}
------------

The human gastric cancer cell lines SNU1, SNU5 and Hs746T were obtained from American Type Culture Collection (Manassas, VA); MKN1, MKN7, MKN45, and NUGC3 were from the Health Science Research Resources Bank (Japan Health Sciences Foundation, Tokyo, Japan); KATO III, MKN28, and HSC39 were from Immuno-Biological Laboratories (Gunma, Japan); and SNU216 was from the Korean Cell Line Bank (Seoul National University, Seoul, Korea). All of the cell lines were maintained under a humidified atmosphere of 5% CO~2~ at 37°C in RPMI 1640 medium (Sigma, St. Louis, MO) supplemented with 10% heat-inactivated FBS (Gibco BRL, Grand Island, NY), penicillin, and streptomycin.

Patients {#s4_2}
--------

A total of 267 patients with histologically confirmed gastric cancer who had undergone surgery at the National Cancer Center Hospital (Tokyo, Japan) between 1996 and 2006 were included in the study. All the patients had an Eastern Cooperative Oncology Group performance status of 0 to 2. One patient was subsequently excluded as a result of an insufficient quantity of DNA extracted from the corresponding tissue specimen. The specimens from the remaining 266 patients were thus analyzed. The present study was approved by the Institutional Review Board of the National Cancer Center Hospital, and informed consent was obtained from all subjects.

Isolation of genomic DNA {#s4_3}
------------------------

Macrodissection of the surgical specimens preserved as FFPE tissue was performed after removal of paraffin in order to select a region of cancer tissue. Genomic DNA was extracted from the cancer tissue with the use of a QIAamp DNA Micro Kit (Qiagen, Hilden, Germany). The DNA concentration of the extracts was determined with a NanoDrop 2000 spectrophotometer (Thermo Scientific, Waltham, MA).

PCR-based determination of MET copy number {#s4_4}
------------------------------------------

The copy number of *MET* was determined with the use of a TaqMan Copy Number Assay \[[@R32]\] and the Hs05005660_cn (intron 16) primer (Applied Biosystems, Foster City, CA). The *TERT* locus was used as the internal reference, and DNA from noncancerous FFPE tissue was used as a normal control. Real-time PCR was performed in a total volume of 20 μL per well containing 10 μL of TaqMan genotyping master mix, 20 ng of genomic DNA, and each primer. The amplification protocol included an initial incubation at 95°C for 10 min followed by 40 cycles of 95°C for 15 s and 60°C for 1 min. The resulting products were detected with the use of ABI Prism 7900HT Sequence Detection System (Applied Biosystems). Data were analyzed with SDS 2.2 software and Copy Caller software (Applied Biosystems).

FISH {#s4_5}
----

*MET* copy number per cell was determined by FISH with the use of the c-met / CEN7p Dual Color FISH Probe (GSP Laboratory, Kawasaki, Japan) \[[@R22]\], where CEN7p is the centromeric region of chromosome 7p. The signals were detected by fluorescence microscopy and were evaluated by independent observers (H.K. and I.O.). After screening all entire sections, images of tumor cells were captured and recorded and the signals for 60 random nuclei were counted for an area where individual cells were recognized in at least 10 representative images. Nuclei with a disrupted boundary were excluded from the analysis. Gene amplification was strictly defined by a mean *MET*/CEN7p copy number ratio of \>2.2, corresponding to a previous definition of *MET* amplification \[[@R16]\]. The presence of polysomy or an equivocal *MET*/CEN7p ratio (1.8 to 2.2) were thus scored as negative for amplification.

Immunoblot analysis {#s4_6}
-------------------

Immunoblot analysis was performed as described previously \[[@R22]\]. Rabbit polyclonal antibodies to phosphorylated human MET (pY1234/pY1235), to total AKT, to phosphorylated AKT, to phosphorylated extracellular signal--regulated kinase (ERK), to phosphorylated or total forms of STAT3 were obtained from Cell Signaling Technology (Danvers, MA); those to total ERK were from Santa Cruz Biotechnology (Santa Cruz, CA); those to total MET were from Zymed/Invitrogen (Carlsbad, CA); and those to β-actin were from Sigma. All antibodies were used at a 1:1000 dilution, with the exception of those to β-actin (1:200).

Cell growth inhibition assay {#s4_7}
----------------------------

Cells were transferred to 96-well flat-bottomed plates and cultured for 24 h before exposure to various concentrations of JNJ38877605 (Janssen Pharmaceutica NV, Beerse, Belgium) or SGX523 (SGX Pharmaceuticals, San Diego, CA) for 72 h. Tetra Color One (5 mmol/L tetrazolium monosodium salt and 0.2 mmol/L 1-methoxy-5-methyl phenazinium methylsulfate; Seikagaku Kogyo, Tokyo, Japan) was then added to each well, and the cells were incubated for 3 h at 37°C before measurement of absorbance at 490 nm with a Multiskan Spectrum instrument (Thermo Labsystems, Boston, MA). Absorbance values were expressed as a percentage of that for nontreated cells, and the IC~50~ values of JNJ38877605 and SGX523 for inhibition of cell growth were determined.

Annexin V binding assay {#s4_8}
-----------------------

The binding of annexin V to cells was measured with the use of an Annexin-V-FLUOS Staining Kit (Roche, Basel, Switzerland). Cells were harvested by exposure to trypsin-EDTA, washed with PBS, and centrifuged at 200 × *g* for 5 min. The cell pellets were resuspended in 100 μL of Annexin-V-FLUOS labeling solution, incubated for 10 to 15 min at 15° to 25°C, and then analyzed for fluorescence with a flow cytometer (FACSCalibur) and Cell Quest software (Becton Dickinson, Franklin Lakes, NJ).

Statistical analysis {#s4_9}
--------------------

Overall survival (OS) curves were estimated with the Kaplan-Meier method and compared with the log-rank test. Other statistical analysis was performed with Student\'s two-tailed *t* test or the chi-square test. A *P* value of \<0.05 was considered statistically significant.
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